Incretin effect: GLP-1, GIP, DPP4

Diabetes Research and Clinical Practice

Volumn 93, Issue SUPPL. 1, 2011, Pages

  Kazafeos, Kyriafeos ^a  

^a ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

Author keywords

Beta cell; Diabetes mellitus; Incretin hormones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 3; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ARTICLE; BLOOD PRESSURE FLUCTUATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; HEART MUSCLE CELL; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREATITIS; SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN-SECRETING CELLS; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84860390325     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/S0168-8227(11)70011-0     Document Type: Article

References (43)

1. Elrick H, Stimmler L, Hlad CJ, Arai Y Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964, 24:1076-1082.
2. Dupre J, Ross SA, Watson D, Brown JC Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973, 37:826-828.
3. Orskov C, Wettergren A, Holst JJ Biological effects and metabolic rates of glucagon-like peptide-17-36 amide and glucagon-like peptide-17-37 in healthy subjects are indistinguishable. Diabetes 1993, 42:658-661.
4. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JE Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in rat islet cell line. Proc Nati Acad Sei U S A 1987, 84:3434-3438.
5. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003, 278:471-478.
6. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
7. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemie clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
8. Wishart JM, Horowitz M, Morris HA, Jones KL, Nauck MA Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 1998, 19(6):1049-1053.
9. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379(6560):69-72.
10. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Nati Acad Sei USA 2009, 106(4):1285-1290.
11. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72(5):603-612.
12. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9(9):1173-1179.
13. Barragán JM, Rodrïguez RE, Blázquez E Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-l-(7-36) amide in rats. Am J Physiol 1994, 266(3 Pt l):E459-E466.
14. Bose AK, Mocanu MM, Carr RD, Yellon DM Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21(4):253-256.
15. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109(8):962-965.
16. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ The GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Published online before print January 16, 2009, doi: 10.2337/db08-1193.
17. Nuche-Berenguer B, Moreno P, Esbrit P, Dapïa S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Peñacarrillo ML Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 2009, 84(6):453-461.
18. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Hoist JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002, 8(7):738-742.
19. Mentlein R, Gallwitz B, Schmidt WE Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-l(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214(3):829-835.
20. Nauck M, Stockman F, Ebert, et al. Reduced incretin effect in type 2 (non-insulin-depentent) diabetes. Diabetologia 1986, 29:46-52.
21. Nauck MA, Heimsaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
22. Meier JJ, Hücking K, Hoist JJ, Deacon CF, Schmiegel WH, Nauck MA Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001, 50(11):2497-2504.
23. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52(2):199-207.
24. Meneilly GS, Bryer-Ash M, Elahi D The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 1993, 16(1):110-114.
25. Nauck MA, Kleine N, Orskov C, Hoist JJ, Wilms B, Creutzfeldt W Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type-2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
26. Eng J, Kleinman WA, Singh K, Singh G, Raufman JP Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
27. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-2000.
28. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
29. Kendal DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1035-1083.
30. Zinman B, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.
31. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodws RG Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
32. Nauck MA, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
33. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
34. Marre M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a suphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009 14 Jan, 10.1111/j.1464-54912009.02666.x.
35. Nauck M, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2008, 32:84-90.
36. Garber A, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
37. Zinman B, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabebtes mellitus (LEAD-4 Met+TZD). Presented at the 44th Annual Meeting of the European Association for the Study of Diabetes, September 7-11, 2008, Rome, Italy.
38. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47.
39. Matthews JE, et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrino] Metab 2008, 93:4810-4817.
40. Kieffer TJ, Mclntosh CH, Pedrson RA Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
41. Deacon CF Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
42. Ahren B, Gomis R, Standl E, Mills D, Schweizer A Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
43. Lankas G, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes 2004, 54:2988-2994.